Tirzepatide vs Semaglutide for Weight Loss: Which Wins in 2026?

# Tirzepatide vs Semaglutide for Weight Loss: Which Wins in 2026?

If you're researching GLP-1 medications for weight loss, you've probably landed on two main options: semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound). Both are effective. Both are injectable. Both require a prescription.

But they're not the same drug, and the clinical trial data shows meaningful differences in outcomes. This is a complete head-to-head breakdown.

Quick Answer

Tirzepatide produces more weight loss on average. In clinical trials, patients on tirzepatide lost 20–22% of body weight versus 14–17% on semaglutide. The gap is real and consistent across multiple studies.

That said, semaglutide is still highly effective — especially at higher doses — and may be the better choice for certain patients.

How Each Drug Works

### Semaglutide: GLP-1 Agonist

Semaglutide mimics one hormone: GLP-1 (glucagon-like peptide-1). It: - Slows gastric emptying (you feel full longer) - Reduces appetite signaling in the brain - Improves insulin sensitivity - Lowers blood sugar

It was originally approved for type 2 diabetes (Ozempic), then reformulated at higher doses for weight loss (Wegovy, 2.4mg/week).

### Tirzepatide: Dual GIP/GLP-1 Agonist

Tirzepatide hits two receptors: GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). The dual mechanism is why it performs better. GIP amplifies the metabolic effects of GLP-1, particularly in fat tissue and the brain's appetite centers.

Originally approved for diabetes (Mounjaro), then approved for weight loss (Zepbound, 2024).

The Clinical Trial Data

### SURMOUNT-1 (Tirzepatide) - Patients: 2,539 adults with obesity, no diabetes - Duration: 72 weeks - Results: - 5mg: 15% average weight loss - 10mg: 19.5% average weight loss - 15mg: 20.9% average weight loss - Nearly 36% of patients on 15mg lost more than 25% of body weight

### STEP-1 (Semaglutide 2.4mg) - Patients: 1,961 adults with obesity, no diabetes - Duration: 68 weeks - Results: - Semaglutide 2.4mg: 14.9% average weight loss - About 32% of patients lost more than 20% of body weight

### Head-to-Head: SURMOUNT-5 (2025) This was the first direct comparison trial — same patient population, randomized to either drug.

| Metric | Tirzepatide 10-15mg | Semaglutide 2.4mg | |--------|---------------------|-------------------| | Average weight loss | 20.2% | 13.7% | | ≥25% body weight loss | 32% | 16% | | Discontinuation rate | 17% | 22% |

Tirzepatide won on every primary outcome. The difference was roughly 47% more weight loss with tirzepatide.

Side Effect Comparison

Both drugs share a similar GI side effect profile because they both act on GLP-1 receptors.

Common side effects (both drugs): - Nausea (most common, usually resolves after first month) - Constipation - Vomiting (less common) - Diarrhea - Fatigue during dose escalation

Key differences: - Tirzepatide patients in SURMOUNT-5 had slightly *lower* discontinuation rates due to side effects (17% vs 22%) - Some patients report tirzepatide has a smoother tolerance curve as dose increases - GIP receptor activation may help offset some of the nausea typical of pure GLP-1 agonists

Neither drug is "easier" on everyone. Individual response varies considerably.

Who Should Consider Tirzepatide

Tirzepatide is likely the better choice if: - You have significant weight to lose (50+ lbs) - You've been on semaglutide and plateaued - You want the highest-evidence drug available - You have type 2 diabetes (tirzepatide has stronger A1C data) - You want the lowest rate of side effects relative to effectiveness

Who Should Consider Semaglutide

Semaglutide may be better if: - You've already had good success on it - You're sensitive to medications and want to start conservatively - You have a contraindication to GIP agonism (rare) - Availability or cost is a significant factor in your area - Your physician recommends it based on your health history

What About Compounded Versions?

Brand-name Mounjaro/Zepbound and Ozempic/Wegovy cost $900–$1,400/month without insurance. Most patients don't have coverage.

Compounded versions use the same active pharmaceutical ingredients at a fraction of the cost: - Compounded tirzepatide: $249–$349/month - Compounded semaglutide: $199–$299/month

The FDA has permitted compounding during shortage periods. As of early 2026, compounded versions remain available through licensed telehealth providers with 503B pharmacy partnerships.

At Marrow, both compounded semaglutide and tirzepatide are available. Our physician consultation includes a recommendation on which is appropriate based on your health history and goals.

The Bottom Line

Tirzepatide produces more weight loss. That's not marketing — it's what every major clinical trial shows, including the head-to-head SURMOUNT-5. The gap is roughly 6–7% more body weight lost on average, which at 200 lbs is 12–14 lbs of additional loss.

For most patients who qualify, tirzepatide is the more powerful option. But the "best" drug is the one your physician clears you for and that you can tolerate long-term.

If you want a physician to review your health history and make a recommendation, [start your intake at Marrow](/start). Most patients receive their medication within a week of approval.